We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Digital Pathology System Provides Exceptional Image Quality Within Seconds

By LabMedica International staff writers
Posted on 02 Aug 2022

A high-performance digital pathology system that delivers exceptional image quality within seconds is setting new standards for laboratories. More...

OptraSCAN’s (Sunnyvale, CA, USA) high-performance OS-Ultra product line of brightfield scanners has a loading capacity of 80 to 480 slides. With no-touch continuous loading, it scans tissues or cells with a 15 mm x 15 mm area at 40x magnification in less than 60 seconds. They produce high-resolution images that can be analyzed further with the help of OptraSCAN's artificial intelligence-based software. This platform is capable of scanning histopathology and cytopathology slides. In addition, it can be configured with 5 to 11 layers for volume scanning or viewed as composite, single layer, fully focused image.

The tray and basket system used by OS-Ultra scanners are designed to efficiently transfer and position slides for scanning and prevent slide handling mistakes. For organizations seeking to scale up operations by increasing throughput, OS Ultra is an efficient, consistent, and accurate solution. OptraSCAN has received CE-IVDR marking for the OS-Ultra scanners, which are available at an extremely affordable price point, including pay-per-scan based OPEX models. OptraSCAN's full digital pathology solutions include scanning devices, image management and viewing software, telepathology software, and image analysis solutions for biomarker and morphometry.

"The CE-IVDR mark will enhance the acceptability of OS-Ultra systems across the globe and strengthen OptraSCAN's mission to improve patient outcomes with affordable and easy to implement digital pathology solutions," said Abhi Gholap, Founder CEO of OptraSCAN.

Related Links:
OptraSCAN 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.